Valuation: Opus Genetics, Inc.

Market Cap 326M 285M 263M 246M 462M 30.71B 472M 3.16B 1.22B 15.18B 1.22B 1.2B 52.63B P/E 2026 *
-3.73x
P/E 2027 * -5.27x
Enterprise Value 326M 285M 263M 246M 462M 30.71B 472M 3.16B 1.22B 15.18B 1.22B 1.2B 52.63B EV / Sales 2026 *
21.4x
EV / Sales 2027 * 22x
Free-Float
88.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+7.53%
1 week-1.72%
Current month-8.26%
1 month-4.76%
3 months-8.05%
6 months+98.02%
Current year+99.00%
1 week 3.62
Extreme 3.62
4.29
1 month 3.62
Extreme 3.62
4.68
Current year 1.88
Extreme 1.88
5.81
1 year 0.9
Extreme 0.9011
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
7
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 31/10/2023
Director of Finance/CFO 52 01/09/2025
President 60 21/10/2024
Director TitleAgeSince
Director/Board Member 77 31/10/2020
Chairman 56 30/11/2019
Director/Board Member 59 31/10/2020
Date Insider Type Main position Quantity % Market Cap.
05-17
The Foundation Fighting Blindness, Inc.
SellCompany -1,700,000 2.0886%
04-22Sell

Chief Operating Officer

4,697 0.0066%
04-22Sell

Chairperson

7,470 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+7.53%-1.72%+309.58%+4.71% 326M
+7.13%+9.97%+55.80%+163.38% 1,077B
+3.99%+11.50%+67.09%+56.27% 613B
+4.20%+17.03%+38.97%+91.19% 448B
+0.99%+4.85%+28.17%+22.04% 332B
+1.82%+8.19%+40.04%+27.45% 293B
+0.22%+6.75%+31.30%+42.64% 286B
+0.73%+8.53%-27.33%-40.29% 215B
+1.56%+6.14%+29.30%+61.91% 193B
+3.26%+3.33%+15.55%+67.87% 159B
Average +3.14%+7.46%+58.85%+49.72% 361.64B
Weighted average by Cap. +3.85%+9.65%+41.78%+81.01%

Financials

2026 *2027 *
Net sales 15.18M 13.31M 12.27M 11.49M 21.54M 1.43B 21.99M 147M 57.06M 708M 57M 55.76M 2.45B 14.83M 13M 11.99M 11.22M 21.04M 1.4B 21.48M 144M 55.75M 691M 55.69M 54.47M 2.4B
Net income -94.49M -82.85M -76.37M -71.5M -134M -8.91B -137M -918M -355M -4.41B -355M -347M -15.28B -67.77M -59.42M -54.77M -51.28M -96.15M -6.39B -98.15M -658M -255M -3.16B -254M -249M -10.96B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26/06/26 US$4.000 +7.53% 7,866,281
25/06/26 US$3.720 +0.27% 982,368
24/06/26 US$3.710 -9.07% 949,086
23/06/26 US$4.080 0.00% 726,733
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.000USD
Average target price
10.56USD
Spread / Average Target
+163.89%

Quarterly revenue - Rate of surprise